Hemophagocytic syndrome (HPS), also called as hemophagocytic lymphohistiocytosis (HLH), is a rare but fatal complication after stem cell transplantation (SCT). Appropriate and prompt intervention is necessary because of a significant risk of graft failure [1] . Most of the patients who developed HPS following SCT described in previous case reports were treated with corticosteroids (CS), high-dose intravenous immunoglobulin (IVIG), low-dose etoposide (VP-16), and/or second salvage SCT [1] [2] [3] . Some cases may not tolerate the salvage SCT because of coexistent complications. To date, prognosis of patients with HPS following SCT described in several previous reports seems considerably poor [1, 4] , and optimal treatment strategy remains to be established.
Tumor necrosis factor (TNF)-α inhibitors such as infliximab, etanercept, and adalimumab are commonly used to treat patients with autoimmune disease including rheumatoid arthritis and inflammatory bowel disease. In addition, several recent reports demonstrated the feasibility of anti-TNF therapy for patients with autoimmune diseaseassociated HLH/macrophage activation syndrome (MAS) [5] [6] [7] , a term used to describe HLH that occurs in patients with systemic juvenile idiopathic arthritis or adult-onset Still's disease. Here we report a patient with Behcet's disease who underwent SCT for secondary myelodysplastic syndrome (MDS). He developed HPS early after SCT followed by secondary graft failure, and was treated with adalimumab. To our knowledge, this is the first report describing the use of anti-TNF-α inhibitor for treatment of HPS occurring after SCT.
The patient is a 7-year-old boy with a 2-year history of intestinal Behcet's disease treated with CS, cyclosporine, and adalimumab. He was referred to our hospital for the purpose of allogeneic SCT because he developed MDS (refractory cytopenia with multilineage dysplasia) with cytogenetic abnormality of monosomy 7. On admission, bone marrow aspiration revealed that he had disease progression to acute myeloid leukemia (AML) with 91% of monosomy 7 in the bone marrow cells based on the fluorescence in situ hybridization. He immediately received AML-oriented chemotherapy consisting of high-dose cytarabine (3 g/m 2 every 12 h for 3 days), VP-16 (100 mg/ m 2 for 5 days), and idarubicin (10 mg/m 2 for 1 day). After one course of chemotherapy, he achieved morphological complete remission, although only 6% of monosomy 7 was detected. He received bone marrow transplantation (BMT) from a human leukocyte antigen-8/8 allele-matched unrelated donor after conditioning with busulfan (19.2 mg/kg) and melphalan (180 mg/m 2 ). Administration of adalimumab was discontinued before the conditioning started, while CS of 1 mg/kg was continued. Tacrolimus and short-term methotrexate were given as graft-versus-host disease (GVHD) prophylaxis. Pre-transplant computed tomography (CT) indicated no evidence of fungal infection. Micafungin was used for prophylaxis of fungal infection. To facilitate engraftment, granulocyte-colony-stimulating factor (G-CSF) was administered from day 7 post BMT. On day 11, high-grade fever developed and serum C-reactive protein level increased (17.8 mg/dL). The tests for 1,3-β-glucan (BG) and Aspergillus galactomannan antigenemia turned positive, and administration of liposomal amphotericin B was started. On the same day, he had a transient hypertensive encephalopathy, and tacrolimus was discontinued.
Successful neutrophil engraftment was achieved on day 18, but low-grade fever continued. Administration of cyclosporine A was started in substitution for tacrolimus on day 19, and mycophenolate mofetil was started on day 22. On day 30, bone marrow aspiration showed normal cellular marrow without active hemophagocytosis, and chimerism analysis using bone marrow mononuclear cells by short tandem repeat-PCR revealed 81.6% of donor chimerism. From the next day, white blood cell (WBC) count began to decrease in spite of continuous G-CSF use. (Fig. 1) .
On day 35, the WBC count decreased to 0.37 × 10 9 /L. Level of serum ferritin was elevated to 2,887 ng/mL, while serum lactate dehydrogenase was not increased. The bone marrow aspiration showed hemophagocytosis with an increase in the proportion of activated macrophages (20%), and decrease in donor chimerism (76.8%). We made a diagnosis of HPS based on the criteria proposed by Henter et al. [8] (five of the eight criteria including fever, splenomegaly, bicytopenia, hemophagocytosis, and hyperferritinemia). Level of soluble interleukin-2 receptor (792 U/mL) was <2400 U/mL, and fasting triglyceride (110 mg/dL) and fibrinogen (2.7 g/L) were within normal range. Natural killer cell activity was not examined. Blood cultures for bacterial and fungal etiology were negative. No viral pathogens, including adenovirus, Epstein-Barr virus, cytomegalovirus, and human herpesvirus-6, were detected in blood. On the same day, CT revealed two huge abscesses located in the liver and mesenterium. Because BG test was consistently positive, some fungus was suspected as an etiology of these abscesses. Therefore, administration of voriconazole was initiated. He received treatments with IVIG and low-dose VP-16 immediately after diagnosis of HPS, but these agents were ineffective. He was contraindicated for a second salvage transplantation because he had pneumonia, and heart failure in addition to intraabdominal abscesses. On day 43, the proportion of activated macrophage in bone marrow further increased, and donor chimerism decreased (59.2%). In addition, CT showed that liver abscess enlarged and invaded into the right atrium through the inferior vena cava. There was no surgical indication due to persistent pancytopenia. As a salvage treatment for treatment-resistant HPS, adalimumab was administered at 40 mg/dose on day 50. After only one infusion, the neutrophil count began to increase at 3 days, and re-engraftment was achieved at 7 days, after administration of adalimumab. Subsequently, proportion of donor chimerism was increased (84.2%). On day 71, he was transferred to another hospital for the management of liver abscess. On day 75, he received needle biopsy of liver abscess and was diagnosed with liver aspergilloma. Despite continued intensive antifungal therapy, CT revealed a new abscess located in pulmonary artery with the suspicion of embolism on day 86. Although he planned to undergo surgical resection of the abscesses, he died of multiple organ failure caused by disseminated aspergillosis on day 99. HPS is a life-threatening disease of hyperinflammation caused by overproduction of cytokines secreted by activated T cells and macrophages, although precise pathophysiology remains to be elucidated [8] . It is suggested that anti-TNF agents inactivate the proinflammatory cytokine TNF by direct neutralization and more complex functions, thus resulting in suppression of inflammation. To date, successful treatments of refractory HLH/MAS using infliximab, a chimeric monoclonal antibody with murine and human sequences [5, 6] , and etanercept, a fusion protein combining the extracellular ligand-binding portion of the human TNF receptor fused with the Fc portion of human IgG1 [7] have been reported. Based on the findings in these reports, our patient received adalimumab, a fully human anti-TNF-α monoclonal antibody, for management of therapy-resistant HPS because he had received this agent regularly for his Behcet's disease until he received BMT. Unfortunately, he died from disseminated invasive aspergillosis finally, however, the effect of adalimumab was remarkable, and he could recover from secondary graft failure. Actually, whether the improvement of HPS was due to the effects of adalimumab alone or of its combination with VP-16 and/or IVIG is uncertain. We could not measure the levels of TNF-alpha before and after adalimumab therapy. However, as signs of hematopoietic recovery were not observed even 2 weeks after the initiation of VP-16 and IVIG, we think that adalimumab might have mainly contributed to the result.
In case of HPS after allogeneic SCT, allo-immune reactions between the donor and recipient may be one of the mechanisms that evoke hypercytokinemia, and the activated macrophages are thought to be of donor origin [1, 3] . In our patient, the origin of macrophages was not examined. Before administration of adalimumab, donor chimerism gradually decreased as the proportion of macrophage increased, suggesting that recipient-derived rather than donor-derived macrophages were involved in the development of HPS, as previously reported [3] . Therefore, the nature of HPS in our patient may be autoimmune diseaseassociated MAS, which was triggered by post-SCT Aspergillus infection.
A close correlation between serum ferritin levels and clinical disease activity or mortality has been reported in patients with HPS [9] . On the other hand, it is described that ferritin is not a specific marker for macrophage activity [10] . In our patient, the level of serum ferritin continued to increase even after HPS calmed down, which may reflect the aggravation of the Aspergillus infection and other conditions.
When using monoclonal antibodies in the post-SCT settings, the risk of infectious complications should be a greater concern because a SCT recipient is considerably immunocompromised [11] . Anti-TNF-α inhibitors have been used for treatment of steroid-refractory acute graftversus-host disease (aGVHD) following SCT [12, 13] . A study showed that 13 of the 21 patients (62%) who received infliximab experienced complete response of GVHD, however some patients developed fungal (48%), bacterial (81%), and viral (67%) infections after infliximab [12] . Actually, it is difficult to determine how infliximab, preceding treatment such as CS, and other factors affected the risk for opportunistic infections. In our patients, although new infectious etiology was not identified after administration of adalimumab, deterioration of existing liver aspergilloma was possibly due to treatment with adalimumab. Since the majority of cases of HPS occur in the setting of an infection [1] , it may be difficult to decide whether these agents should be administered. However, these infections will persist and cause the patients' conditions to worsen unless HPS subsides, thus warranting the need for additional immunosuppressive treatment, or salvage SCT. Given that only a few patients responded to treatment of HPS following SCT, and with considerably poor post-SCT HPS prognosis [1, 4] , adalimumab could be an effective treatment option.
